Feltl and Company has published a research report on Synovis Life Technologies (NASDAQ: SYNO) and has downgraded the company from Hold to Sell after showing trading levels near Baxter International's (NYSE: BAX) $28/share cash offer.
NEW YORK, NY -- (Marketwire) -- 12/15/11 -- Levi & Korsinsky notifies investors of Synovis Life Technologies, Inc. ("Synovis" or the "Company") (NASDAQ: SYNO) of claims of breaches of fiduciary duty and other violations of state law against the board
Good morning traders and investors,
The stock futures are down but only slightly. We will probably see some sideway action today.
Here are some possible trades.
Residential Construction and Auto Parts Industry took a big hit yesterday...
The Trading Radar highlights key earnings and economic announcements for tomorrow's trading session:
Before The Market Opens
MBA Mortgage Index - no Street consensus
Export Prices: ex. ag - no Street...
Endocyte (Nasdaq: ECYT) 63.5% LOWER; an independent review of the PRECEDENT trial showed a decrease in the benefit compared to the original analysis. An RBC analyst said the results increase Phase 3 clinical timing and regulatory EU risk. Baird...
Stifel Nicolaus has initiated coverage on the following companies:
Natus Medical Incorporated (NASDAQ: BABY) Hold
Synovis Life Technologies (NASDAQ: SYNO) Hold
Teleflex (NYSE: TFX) Buy, $65 PT
(c) 2011 Benzinga.com. All rights reserved....
Synovis Life Technologies, Inc. (NASDAQ: SYNO), a diversified medical device company, announced today that Richard W. Kramp, president and chief executive officer, and Brett A. Reynolds, chief financial officer will present at the ROTH 23rd Annual...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.